Ferrostatin-1 attenuates pathological angiogenesis in oxygen-induced retinopathy via inhibition of ferroptosis

Exp Eye Res. 2023 Jan:226:109347. doi: 10.1016/j.exer.2022.109347. Epub 2022 Dec 9.

Abstract

Retinopathy of prematurity (ROP) is a vision-threatening ocular disease that occurs in premature infants, but the underlying mechanism is still unclear. Since oxidative stress has been well documented in the ROP development, we aimed to investigate whether ferroptosis, a new type of cell death characterized by lipid peroxidation and iron overload, is also involved in ROP. We detected the lipid peroxidation, oxidative stress and the expression of ferroptosis markers in the retina of mouse model of oxygen-induced retinopathy. After ferroptosis inhibitor, ferrostatin-1, was administered by intravitreal injection, ferroptosis marker, lipid peroxidation, retinal vasculature and glial cell activation were examined. We found decreased expression of SLC7A11 and GPX4, increased expression of FTH1 and TFRC, as well as increase of lipid peroxidation in the retina of OIR mice. Ferrostatin-1 administration significantly reduced lipid peroxidation, and also reversed the change of ferroptosis marker. Neovascular area and avascular area were suppressed and the pathological vasculature changes including acellular vessels and ghost pericytes were decreased. Microglial cell and Müller cell activation was not evidently influenced by ferrostatin-1 treatment. Our findings suggest that ferroptosis is involved in the pathological angiogenesis and might be a promising target for ROP therapy.

Keywords: Angiogenesis; Ferroptosis; Ferrostatin-1; Oxidative stress; Oxygen-induced retinopathy; Retina.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Ferroptosis* / drug effects
  • Ferroptosis* / physiology
  • Humans
  • Infant, Newborn
  • Mice
  • Neovascularization, Pathologic* / drug therapy
  • Neovascularization, Pathologic* / pathology
  • Oxidative Stress
  • Oxygen / toxicity
  • Retinopathy of Prematurity* / drug therapy
  • Retinopathy of Prematurity* / pathology

Substances

  • ferrostatin-1
  • Oxygen